Biotech Intercept Pharmaceuticals (ICPT) was riding high on an upgrade and multiple price-target increases after it issued new data late Monday on its fatty-liver-disease drug candidate. Intercept Pharma stock vaulted 31% in early trading on the stock market today, near 346, a four-month high. Monday’s data, which Intercept included in its Q2 financial report, provided more details on the mid-stage clinical trial of obetacholic acid (OCA) for
Intercept Pharmaceuticals (ICPT) released new data on its experimental fatty liver drug showing the treatment is effective and has less-severe side effects than previous feared, sending shares soaring 58% to 374 in late trading on the stock market today. The biotech tested obeticholic acid on non-alcoholic fatty liver disease, for which there is no current approved treatment. The drug stopped liver scarring in 46% of patients vs. 21% taking a
Intercept Pharmaceuticals (ICPT) said Thursday that it had stopped a phase-two clinical trial of a liver-disease drug because it had already met its endpoint, sending the stock soaring 245% to near 270 in morning trading in the stock market today. The phase-two trial had been testing a substance called obeticholic acid (OCA) in patients with nonalcoholic steatohepatitis, in which the liver can be damaged by excessive fat accumulated around it.